These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19060856)

  • 41. Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.
    Wang GN; Reinkensmeier G; Zhang SW; Zhou J; Zhang LR; Zhang LH; Butters TD; Ye XS
    J Med Chem; 2009 May; 52(10):3146-9. PubMed ID: 19397268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The unlicensed lives of antidepressants in India: generic drugs, unqualified practitioners, and floating prescriptions.
    Ecks S; Basu S
    Transcult Psychiatry; 2009 Mar; 46(1):86-106. PubMed ID: 19293281
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharma Dynamics: targeting safe, effective and affordable medication for South Africa and neighbouring countries.
    Cardiovasc J Afr; 2009; 20(1):85. PubMed ID: 19287824
    [No Abstract]   [Full Text] [Related]  

  • 44. Bilski blundering biotech.
    Simmons WJ
    Nat Biotechnol; 2009 Mar; 27(3):245-8. PubMed ID: 19270670
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Biosimilar: can we manage biopharmaceutical heterogeneity?].
    Ranieri E
    G Ital Nefrol; 2008; 25(3):275. PubMed ID: 18473296
    [No Abstract]   [Full Text] [Related]  

  • 47. [Generics in psychiatry--do they have the same therapeutic equivalence as the original?].
    Kasper S; Lentner S
    Neuropsychiatr; 2008; 22(4):221-2. PubMed ID: 19080992
    [No Abstract]   [Full Text] [Related]  

  • 48. Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span.
    Sanchez PE; Navarro FP; Fares RP; Nadam J; Georges B; Moulin C; Le Cavorsin M; Bonnet C; Ryvlin P; Belmeguenai A; Bodennec J; Morales A; Bezin L
    J Comp Neurol; 2009 Jun; 514(4):403-14. PubMed ID: 19330822
    [TBL] [Abstract][Full Text] [Related]  

  • 49. European Union regulatory draft guidance on biogenerics containing recombinant human erythropoietin.
    Trkulja V
    Croat Med J; 2006 Feb; 47(1):183-7. PubMed ID: 16489715
    [No Abstract]   [Full Text] [Related]  

  • 50. [Do health services benefit from exchange of preparations in pharmacies?].
    Ekholm ML
    Lakartidningen; 2007 Nov 14-20; 104(46):3476. PubMed ID: 18074614
    [No Abstract]   [Full Text] [Related]  

  • 51. Pharmaceuticals and medical devices: FDA oversight.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
    [No Abstract]   [Full Text] [Related]  

  • 52. Dynogen's SPAC.
    Osborne R
    Nat Biotechnol; 2008 Apr; 26(4):360. PubMed ID: 18391998
    [No Abstract]   [Full Text] [Related]  

  • 53. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biogen Idec goes on the auction block.
    Osborne R
    Nat Biotechnol; 2007 Dec; 25(12):1335-6. PubMed ID: 18066011
    [No Abstract]   [Full Text] [Related]  

  • 55. [Anti-aging preparations--a lucrative industry. Immortality is a meaningless luxury, according to Darwin's theses].
    Viidik A
    Lakartidningen; 2006 Aug 9-22; 103(32-33):2285-6. PubMed ID: 16955574
    [No Abstract]   [Full Text] [Related]  

  • 56. Are patent expirations the answer to improving patient adherence?
    Klepser DG
    Am J Manag Care; 2008 Dec; 14(12):787-8. PubMed ID: 19067495
    [No Abstract]   [Full Text] [Related]  

  • 57. Superfamily structure and biotech drug development.
    Edgington SM
    Biotechnology (N Y); 1992 Dec; 10(12):1529-34. PubMed ID: 1369421
    [No Abstract]   [Full Text] [Related]  

  • 58. [Only similar, not the same].
    Med Monatsschr Pharm; 2007 Jan; 30(1):1. PubMed ID: 17260641
    [No Abstract]   [Full Text] [Related]  

  • 59. [Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].
    Mellstedt H
    Lakartidningen; 2009 Jun 3-9; 106(23):1563-6. PubMed ID: 19583014
    [No Abstract]   [Full Text] [Related]  

  • 60. Relationships of P53 and Bak with EPO and EPOR in human colorectal cancer.
    Baltaziak M; Koda M; Wincewicz A; Sulkowska M; Kanczuga-Koda L; Sulkowski S
    Anticancer Res; 2009 Oct; 29(10):4151-6. PubMed ID: 19846965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.